STOCK TITAN
  1. Home
  2. Sec-filings
  3. BCDA
  4. [Form 4] BioCardia, Inc. Insider Trading Activity

BioCardia (BCDA) SVP awarded 39,521 RSUs fully vesting on June 29, 2026

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

GILLIS EDWARD M reported acquisition or exercise transactions in this Form 4 filing.

BioCardia, Inc. reported that Senior Vice President, Devices, Edward M. Gillis received a grant of 39,521 shares of common stock on June 29, 2026. These were issued as restricted stock units awarded as compensation in lieu of cash, at a reference value of $1.20 per share. All of the RSUs vested on June 29, 2026, and his directly held common stock position increased to 71,395 shares after the grant.

Positive

  • None.

Negative

  • None.
Insider GILLIS EDWARD M
Role Senior Vice President, Devices
Type Security Shares Price Value
Grant/Award Common Stock 39,521 $1.20 $47K
Holdings After Transaction: Common Stock — 71,395 shares (Direct, null)
Footnotes (1)
  1. [object Object]
RSUs granted 39,521 shares Restricted stock units awarded as compensation in lieu of cash
RSU value per share $1.20 per share Reference price for the RSU grant
Total shares after grant 71,395 shares Directly held BioCardia common stock following the transaction
Vesting date June 29, 2026 100% of RSUs vested on this date
restricted stock units ("RSUs") financial
"The reported securities represent restricted stock units ("RSUs"), each of which represents a contingent right..."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
contingent right financial
"each of which represents a contingent right to receive one share of the Issuer's common stock..."
compensation in lieu of cash financial
"common stock awarded as compensation in lieu of cash. 100% of the RSUs vested..."
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
GILLIS EDWARD M
(Last)(First)(Middle)
C/O BIOCARDIA, INC.
320 SOQUEL WAY
(Street)
SUNNYVALE CALIFORNIA 94085
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
BioCardia, Inc. [ BCDA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Senior Vice President, Devices
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/29/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/29/2026A39,521(1)A$1.2(1)71,395D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The reported securities represent restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock awarded as compensation in lieu of cash. 100% of the RSUs vested on June 29, 2026.
/s/ David McClung, by power of attorney07/01/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did BioCardia (BCDA) report for Edward M. Gillis?

BioCardia reported that Senior Vice President, Devices, Edward M. Gillis received 39,521 restricted stock units of common stock as compensation in lieu of cash. All units vested on June 29, 2026, increasing his directly held common stock to 71,395 shares.

Was the BioCardia (BCDA) Form 4 transaction an open-market buy or sell?

The Form 4 transaction was not an open-market buy or sell. It reflects a grant of 39,521 restricted stock units awarded as compensation in lieu of cash, which vested in full on June 29, 2026, and increased the insider’s shareholdings.

How many BioCardia (BCDA) shares does Edward M. Gillis hold after this grant?

After the reported grant, Edward M. Gillis directly holds 71,395 shares of BioCardia common stock. This total includes the 39,521 restricted stock units that were awarded as compensation and fully vested on June 29, 2026, according to the Form 4 filing.

What are the key terms of the BioCardia (BCDA) restricted stock units granted?

The restricted stock units each represent a contingent right to receive one share of BioCardia common stock. A total of 39,521 RSUs were granted as compensation in lieu of cash, and 100% of these units vested on June 29, 2026, per the footnote disclosure.

At what price were the BioCardia (BCDA) RSUs valued in the Form 4?

The 39,521 restricted stock units granted to Edward M. Gillis were reported with a reference price of $1.20 per share. This price is used in the Form 4 to indicate the value of the equity-based compensation awarded instead of a cash payment.